Max Nisen, Columnist

How Pharma Can Get Trump Off Its Back

Voluntary curbs could fend off the threat of Medicare negotiation.

February 8, 2017 at 3:42 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

Drug pricing is a conundrum for the country, and apparently for Donald Trump too.

Last week, some pharma CEOs came out of a meeting with the new president believing he'd dropped his previously stated support for direct Medicare negotiation of drug prices. But at a press conference on Tuesday, Press Secretary Sean Spicer said Trump had not, in fact, dropped that support.